Tobira Therapeutics Inc. (Nasdaq: TBRA) reported disappointing results from a Phase 2b clinical trial of cenicriviroc to treat liver disease. Shares of the biopharmaceutical plummeted $6.75 to close at $4.50.
Tobira Therapeutics disappoints
July 25, 2016 at 18:27 PM EDT
